217 related articles for article (PubMed ID: 32220969)
1. Cabozantinib Reverses Renal Cell Carcinoma-mediated Osteoblast Inhibition in Three-dimensional Coculture
Pan T; Martinez M; Hubka KM; Song JH; Lin SC; Yu G; Lee YC; Gallick GE; Tu SM; Harrington DA; Farach-Carson MC; Lin SH; Satcher RL
Mol Cancer Ther; 2020 Jun; 19(6):1266-1278. PubMed ID: 32220969
[TBL] [Abstract][Full Text] [Related]
2. BIGH3 Promotes Osteolytic Lesions in Renal Cell Carcinoma Bone Metastasis by Inhibiting Osteoblast Differentiation.
Pan T; Lin SC; Yu KJ; Yu G; Song JH; Lewis VO; Bird JE; Moon B; Lin PP; Tannir NM; Jonasch E; Wood CG; Gallick GE; Yu-Lee LY; Lin SH; Satcher RL
Neoplasia; 2018 Jan; 20(1):32-43. PubMed ID: 29190493
[TBL] [Abstract][Full Text] [Related]
3. Cabozantinib inhibits prostate cancer growth and prevents tumor-induced bone lesions.
Dai J; Zhang H; Karatsinides A; Keller JM; Kozloff KM; Aftab DT; Schimmoller F; Keller ET
Clin Cancer Res; 2014 Feb; 20(3):617-30. PubMed ID: 24097861
[TBL] [Abstract][Full Text] [Related]
4. Effects of cabozantinib on bone turnover markers in real-world metastatic renal cell carcinoma.
Ratta R; Verzoni E; Mennitto A; Pantano F; Martinetti A; Raimondi A; Sepe P; Sottotetti E; Mennitto R; Morelli D; Santini D; de Braud FG; Procopio G
Tumori; 2021 Dec; 107(6):542-549. PubMed ID: 33153416
[TBL] [Abstract][Full Text] [Related]
5. Cabozantinib inhibits tumor growth and metastasis of a patient-derived xenograft model of papillary renal cell carcinoma with MET mutation.
Zhao H; Nolley R; Chan AMW; Rankin EB; Peehl DM
Cancer Biol Ther; 2017 Nov; 18(11):863-871. PubMed ID: 27715452
[TBL] [Abstract][Full Text] [Related]
6. Dual targeting c-met and VEGFR2 in osteoblasts suppresses growth and osteolysis of prostate cancer bone metastasis.
Lee C; Whang YM; Campbell P; Mulcrone PL; Elefteriou F; Cho SW; Park SI
Cancer Lett; 2018 Feb; 414():205-213. PubMed ID: 29174801
[TBL] [Abstract][Full Text] [Related]
7. Three-dimensional (3D) culture of bone-derived human 786-O renal cell carcinoma retains relevant clinical characteristics of bone metastases.
Pan T; Fong EL; Martinez M; Harrington DA; Lin SH; Farach-Carson MC; Satcher RL
Cancer Lett; 2015 Aug; 365(1):89-95. PubMed ID: 26004343
[TBL] [Abstract][Full Text] [Related]
8. Erlotinib inhibits osteolytic bone invasion of human non-small-cell lung cancer cell line NCI-H292.
Furugaki K; Moriya Y; Iwai T; Yorozu K; Yanagisawa M; Kondoh K; Fujimoto-Ohuchi K; Mori K
Clin Exp Metastasis; 2011 Oct; 28(7):649-59. PubMed ID: 21688034
[TBL] [Abstract][Full Text] [Related]
9. Antitumor agent cabozantinib decreases RANKL expression in osteoblastic cells and inhibits osteoclastogenesis and PTHrP-stimulated bone resorption.
Stern PH; Alvares K
J Cell Biochem; 2014 Nov; 115(11):2033-8. PubMed ID: 25042887
[TBL] [Abstract][Full Text] [Related]
10. The role of versican G3 domain in regulating breast cancer cell motility including effects on osteoblast cell growth and differentiation in vitro - evaluation towards understanding breast cancer cell bone metastasis.
Du WW; Fang L; Yang W; Sheng W; Zhang Y; Seth A; Yang BB; Yee AJ
BMC Cancer; 2012 Aug; 12():341. PubMed ID: 22862967
[TBL] [Abstract][Full Text] [Related]
11. Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial.
Escudier B; Powles T; Motzer RJ; Olencki T; Arén Frontera O; Oudard S; Rolland F; Tomczak P; Castellano D; Appleman LJ; Drabkin H; Vaena D; Milwee S; Youkstetter J; Lougheed JC; Bracarda S; Choueiri TK
J Clin Oncol; 2018 Mar; 36(8):765-772. PubMed ID: 29309249
[TBL] [Abstract][Full Text] [Related]
12. Rapid modification of the bone microenvironment following short-term treatment with Cabozantinib in vivo.
Haider MT; Hunter KD; Robinson SP; Graham TJ; Corey E; Dear TN; Hughes R; Brown NJ; Holen I
Bone; 2015 Dec; 81():581-592. PubMed ID: 26279137
[TBL] [Abstract][Full Text] [Related]
13. Preclinical evaluation of imaging biomarkers for prostate cancer bone metastasis and response to cabozantinib.
Graham TJ; Box G; Tunariu N; Crespo M; Spinks TJ; Miranda S; Attard G; de Bono J; Eccles SA; Davies FE; Robinson SP
J Natl Cancer Inst; 2014 Apr; 106(4):dju033. PubMed ID: 24634505
[TBL] [Abstract][Full Text] [Related]
14. Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castration-resistant prostate cancer.
Di Nunno V; Cimadamore A; Santoni M; Scarpelli M; Fiorentino M; Ciccarese C; Iacovelli R; Cheng L; Lopez-Beltran A; Massari F; Montironi R
Future Oncol; 2018 Oct; 14(25):2559-2564. PubMed ID: 30141348
[No Abstract] [Full Text] [Related]
15. The glutaminase inhibitor telaglenastat enhances the antitumor activity of signal transduction inhibitors everolimus and cabozantinib in models of renal cell carcinoma.
Emberley E; Pan A; Chen J; Dang R; Gross M; Huang T; Li W; MacKinnon A; Singh D; Sotirovska N; Steggerda SM; Wang T; Parlati F
PLoS One; 2021; 16(11):e0259241. PubMed ID: 34731180
[TBL] [Abstract][Full Text] [Related]
16. A bone-seeking clone exhibits different biological properties from the ACHN parental human renal cell carcinoma in vivo and in vitro.
Wang J; Chen A; Yang C; Zeng H; Qi J; Guo FJ
Oncol Rep; 2012 Apr; 27(4):1104-10. PubMed ID: 22139406
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological evidence for the bone-autonomous contribution of the NFκB/β-catenin axis to breast cancer related osteolysis.
Marino S; Bishop RT; Logan JG; Mollat P; Idris AI
Cancer Lett; 2017 Dec; 410():180-190. PubMed ID: 28965856
[TBL] [Abstract][Full Text] [Related]
18. BMP-2 inhibits tumor-initiating ability in human renal cancer stem cells and induces bone formation.
Wang L; Park P; La Marca F; Than KD; Lin CY
J Cancer Res Clin Oncol; 2015 Jun; 141(6):1013-24. PubMed ID: 25431339
[TBL] [Abstract][Full Text] [Related]
19. Cabozantinib in the treatment of metastatic renal cell carcinoma - final data analysis from four oncology centers in the Czech Republic.
Richter I; Poprach A; Zemánková A; Büchler T; Bartoš J; Šámal V; Študentová H; Rozsypalová A; Dvořák J; Brom O; Melichar B
Klin Onkol; 2021; 34(5):392-400. PubMed ID: 34915708
[TBL] [Abstract][Full Text] [Related]
20. Activity of cabozantinib in radioresistant brain metastases from renal cell carcinoma: two case reports.
Négrier S; Moriceau G; Attignon V; Haddad V; Pissaloux D; Guerin N; Carrie C
J Med Case Rep; 2018 Nov; 12(1):351. PubMed ID: 30474572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
